SEC Tracker
Get the app

Oragenics OGEN

Oragenics FY 2024: net loss $10.6M; diluted EPS −$1.60

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.25
Material contract
Exhibit 10.26
Material contract
Exhibit 10.27
Material contract
Exhibit 10.28
Material contract

Key figures from this report

These are the numbers Oragenics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$10.6MAgainst −$20.7M in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$1.60Against −$9.18 in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$865K−75% from $3.5M in FY 202310-K balance sheet, on EDGAR
  4. Cash from operations−$8.6MAgainst −$7.3M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Oragenics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. MetaVia MTVA public float $3M, Jun 30, 2025
  2. Inhibitor Therapeutics INTI public float $3M, Jun 30, 2025
  3. PTC Therapeutics PTCT public float $3M, Jun 30, 2025
  4. Integrated Biopharma INBP public float $3M, Dec 31, 2025
  5. Enveric Biosciences ENVB public float $4M, Jun 30, 2025